Skip to main content
Clinical Trials/NL-OMON42320
NL-OMON42320
Recruiting
Not Applicable

Treatment of chronic hepatitis C infection with direct acting antivirals: effects on liver fibrosis and patient reported outcomes - DURACE study

Afdeling Maag-, Darm en Leverziekten0 sites100 target enrollmentTBD

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Hepatitis C infection
Sponsor
Afdeling Maag-, Darm en Leverziekten
Enrollment
100
Status
Recruiting
Last Updated
2 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
2 years ago
Study Type
Observational invasive

Investigators

Sponsor
Afdeling Maag-, Darm en Leverziekten

Eligibility Criteria

Inclusion Criteria

  • \- Chronic hepatitis C
  • \- Age \> 18 years
  • \- METAVIR score F3\-F4 (classified by liver biopsy or Fibroscan score \>9,5 kPa)
  • \- Status after liver transplantation or on the waiting list for liver transplantation
  • \- Severe extra hepatic disease (HCV\-related skin disease like prophyria cutanea tarda or leukocytoclastic vasculitis; or HCV related renal impairment secondary to cryoglobulinemia

Exclusion Criteria

  • \- Patients who don't meet the criteria for DAA treatment
  • \- Patients who are not able to visit the outpatient clinic at regular basis

Outcomes

Primary Outcomes

Not specified

Similar Trials

Active, not recruiting
Not Applicable
Evaluation of chronic hepatitis C treatment with PEG-IFN ALFA-2a and ribavirin in HIV-positive subjects with persistently normal transaminase levels. - Treatment of co-infected patients with normal ALTTreatment of adult patients with hystologically demonstrated chronic C hepatitis without hepatic failure and HCV-RNA positive, treatment of patients with normal ALT and with HIV/HCV co-infection.MedDRA version: 9.1Level: LLTClassification code 10019744Term: Hepatitis C
EUCTR2007-005698-76-ITAZIENDA OSPEDALIERA L. SACCO (A.O. DI RILIEVO NAZIONALE)
Active, not recruiting
Phase 1
Direct acting antiviral therapy of hepatitis C in Denmark: treatment response, adverse events and resistance associated variantsPatients with chronic hepatitis CMedDRA version: 19.1Level: LLTClassification code 10074391Term: Chronic hepatitis C virus genotype 1System Organ Class: 100000004862Therapeutic area: Diseases [C] - Virus Diseases [C02]
EUCTR2015-001956-31-DKDepartment of Infectious Diseases, Copenhagen University Hospital, Hvidovre.111
Completed
Not Applicable
Retreatment of hepatitis C non-responsive to Interferon: a placebo controlled randomised trial of Ribavirin monotherapy versus combination therapy with Ribavirin and Interferon in 121 patients in the BeneluxChronic hepatitis CInfections and InfestationsHepatitis
ISRCTN53821378Schering Plough International (USA)117
Completed
Phase 2
A pilot phase II open-label study of oglufanide disodium in patients with chronic hepatitis CChronic hepatitis CInfection - Other infectious diseases
ACTRN12607000418471Implicit Bioscience Pty Ltd17
Completed
Not Applicable
TREATMENT OF PATIENTS WITH CHRONIC HEPATITIS C (HCC) USING PEG-INTERFERON ALPHA 2B AND RIBAVIRINE
PER-039-01SCHERING PLOUGH RESEARCH INSTITUTE,